Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

NQO1-targeted indolequinone 23-hydroxy betulinic acid derivative and preparation method and application thereof

A technology of indole quinones and derivatives, applied in the field of medicinal chemistry, can solve the problems of unclear mechanism and poor pharmacokinetic properties, and achieve the effect of good activity, good inhibitory effect and low toxicity

Active Publication Date: 2021-08-24
CHINA PHARM UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

23-HBA has unique antitumor activity, but its clinical application is limited due to its unclear mechanism and poor pharmacokinetic properties

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • NQO1-targeted indolequinone 23-hydroxy betulinic acid derivative and preparation method and application thereof
  • NQO1-targeted indolequinone 23-hydroxy betulinic acid derivative and preparation method and application thereof
  • NQO1-targeted indolequinone 23-hydroxy betulinic acid derivative and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037]

[0038] 3-O-[(5-methoxy-1-methyl-4,7-dioxo-4,7-dihydro-1H-indole)-3-methoxyacyl)-propionyl)] -23-Acetyl-lupine-20(29)-en-28-oic acid

[0039] The targeting group indoloquinone was dissolved in dichloromethane (10mL), succinic anhydride (309mg, 2.71mmol) and DMAP (110mg, 0.91mmol) were added thereto, heated to 45°C, reacted for 1.5h, added water, Dichloromethane (50mL×3) was extracted, the organic phase was washed with water and saturated sodium chloride, dried over anhydrous sodium sulfate, concentrated, and column chromatography (dichloromethane:methanol=100:1) gave yellow intermediate 1;

[0040] The 23-HBA derivative (50mg, 0.083mmol) protected by acetyl group at the 23rd position was dissolved in anhydrous DCM (4mL), and Intermediate 1 (39.8mg, 0.13mmol), EDCI (24mg, 0.13mmol) and DMAP (17mg, 0.13mmol), reacted at room temperature for 5h, extracted with EA (20mL×3), added 1N hydrochloric acid (2mL), combined organic layers, washed with saturated NaHCO3 solution...

Embodiment 2

[0042]

[0043] 3-O-[(5-methoxy-1-methyl-4,7-dioxo-4,7-dihydro-1H-indole)-3-methoxyacyl)-butyryl)] -23-Acetyl-lupine-20(29)-en-28-oic acid

[0044] The synthesis method refers to the synthesis of Example 1, 30.5%. 1 H NMR (300MHz, Chloroform-d) δ 6.86(s, 1H), 5.66(s, 1H), 5.33(s, 2H), 4.77(s, 1H), 4.64(s, 1H), 3.94(s, 3H ), 3.85(s, 4H), 3.73(s, 1H), 3.62-3.51(m, 1H), 3.09-3.02(s, 1H), 2.45-2.34(m, 5H), 2.27-2.19(m, 2H ), 1.72(s, 1H), 1.33(s, 3H), 0.99(s, 3H), 0.90(s, 3H), 0.80(s, 3H); 13 C NMR (125MHz, Chloroformm-d) δ179.0, 177.4, 171.9, 160.3, 152.5, 129.5, 121.5, 119.4, 106.8, 72.2, 67.1, 58.4, 58.3, 58.0, 56.5, 50.7, 49.2, 48.2, 46.9, 43.6 , 42.5, 42.2, 40.8, 38.5, 37.1, 36.3, 36.0, 34.0, 31.4, 30.2, 29.7, 29.7, 25.5, 23.5, 22.6, 20.9, 19.4, 16.6, 15.1, 14.7, 11.8. / z: calculated for C 48 h 65 NO 11 Na[M+Na] + :854.4450, found: 854.4458.

Embodiment 3

[0046]

[0047] 3-Hydroxy-23-O-[(5-methoxy-1-methyl-4,7-dioxo-4,7-dihydro-1H-indole)-3-methoxyacyl)- Butyryl)]-lupine-20(29)-en-28-oic acid

[0048] The synthetic method refers to the synthesis of Example 1, 33.7%. 1 H NMR (300MHz, Chloroform-d) δ6.84(s, 1H), 5.70(s, 1H), 5.28(d, J=2.7Hz, 2H), 4.75(s, 1H), 4.62(s, 1H) , 3.96(s, 3H), 3.84(s, 4H), 3.49-3.35(m, 1H), 3.02-2.99(m, 1H), 2.47-2.39(m, 4H), 2.30-2.17(m, 2H) , 2.02-1.95(m, 5H), 1.70(s, 3H), 1.30(s, 3H), 0.94(s, 3H), 0.89(s, 3H), 0.87(s, 3H); 13 C NMR (75MHz, Chloroform-d) δ 195.3, 179.1, 177.4, 173.3, 172.7, 162.1, 160.4, 150.4, 137.7, 129.6, 121.5, 119.5, 106.8, 72.4, 61.9, 58.1, 58.0, 56.6, 52.3, 49 47.0, 44.0, 42.4, 42.1, 40.7, 38.4, 37.1, 36.9, 36.4, 33.6, 33.2, 31.5, 30.2, 29.7, 28.2, 25.5, 20.2, 19.4, 16.8, 16.0, 14.2, 11.8; HR-MS(ESI) m / z: calculated for C 46 h 63 NO 10 Na[M+Na] + :812.4344, found: 812.4351.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a quinone oxidoreductase (NQO1) targeted indoquinone 23-hydroxy betulinic acid derivative and a preparation method and application thereof. The compound is good in activity and small in toxicity, has a remarkable inhibition effect on tumor cell growth, particularly has a better inhibition effect on NQO1 high-expression tumor cells, and can be used for further preparing novel anti-tumor drugs. The preferably treated tumor diseases are lung cancer, liver cancer, melanoma and colon cancer.

Description

technical field [0001] The invention relates to medicinal chemistry, in particular to quinone oxidoreductase (NQO1) targeted indole quinone 23-hydroxy betulinic acid derivatives, preparation method and application. It specifically relates to 23-hydroxybetulinic acid derivatives (I), (II) and (III), which are novel derivatives of indolequinone 23-hydroxybetulinic acid targeted by NQO1. Background technique [0002] Targeted anti-tumor prodrugs refer to compounds that can specifically transform or release the original drug with anti-tumor activity in tumor cells. Targeted anti-tumor prodrugs can greatly improve the shortcomings of chemotherapy drugs such as high toxicity and poor selectivity, and play a vital role in targeted tumor therapy. DTD (DT-diaphorase, EC 1.6.99.2) is a homodimeric protein with a 27kda subunit, which has two, three and four phenotypes in mice, rats and humans, respectively. In humans, the predominant phenotype present is NAD(P)H:quinone oxidoreductas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07J63/00A61K31/56A61P35/00
CPCC07J63/008A61P35/00
Inventor 徐进宜朱华健徐盛涛刘洁鲁丽雪姚鸿陈哲生杨冬华叶文才
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com